Category: Accuray Inc.Syndicate content

FDA clears St. Jude's first-to-market hybrid FFR/OCT blood vessel imaging system | Regulatory Roundup

October 26, 2011 by MassDevice staff

St. Jude's hybrid FFR/OCT blood vessel imaging system gets the green light from the FDA.

St. Jude

St. Jude Medical Inc. (NYSE:STJ) got the FDA's green light for the U.S. market's first combined FFR/OCT blood vessel imaging system for diagnosis and treatment of coronary artery disease.

The Ilumien system combines St. Jude's PressureWire Aeris wireless fractional flow reserve imaging technology, which allows physicians to visualize blood vessel characteristics, and its Extreme Resolution optical coherence tomography, which helps evaluate the severity of blood flow blockages in coronary arteries.

Ballantyne takes CFO post at Avedro | Personnel Moves

September 28, 2011 by MassDevice staff

Avedro Inc. appoints med tech veteran C. Evan Ballantyne as its chief financial officer.

Avedro

Waltham, Mass.-based medical device and pharmaceutical company Avedro appointed industry veteran C. Evan Ballantyne as its new chief financial officer.

Prior to the appointment, Ballantyne was the VP & CFO of biopharmaceutical company Clinical Data Inc., chief financial officer of Beverly, Mass.-based ZymeQuest, and vice president at chief operating officer at the ACNielsen Corporation.

Accuray slips into the red in Q4, FY2011 | Earnings Roundup

September 21, 2011 by MassDevice staff

Accuray Inc. put red ink into its ledger book for the fourth quarter and full fiscal 2011, as it paid down its $300 million acquisition of rival TomoTherapy; also, Analogic posts double-digit sales and profit gains; Solos Endoscopy reports sales increase; Pro-Dex swings to black ink; Revolutions Medical posts big losses; Visual Healthcare rides the ACA to profitability.

Accuray

Accuray Inc. (NSDQ:ARAY) may be the fish that swallowed the whale, but it might have bitten off more than it can chew judging from its fourth-quarter and fiscal 2011 results.

The Sunnyvale, Calif.-based radiosurgery device maker paid $300 million for its larger rival TomoTherapy in March. That acquisition sent ARAY into the red for both the quarter and full year.

Accuray ups offering to $100 million | Funding Roundup

August 2, 2011 by MassDevice staff

Accuray's initial proposal of $75 million in convertible senior notes rises to $100 million in official pricing.

Updated: 08/02/2011 1:30 p.m.

Accuray

Accuray Inc. (NSDQ:ARAY) priced its proposed offering higher than previous estimates, coming in at $100 million in 3.75 percent convertible senior notes made available to institutional investors.

The sale was set to close yesterday, according to SEC filings.

Becton Dickinson swaps out CEO | Personnel Moves

July 28, 2011 by MassDevice staff

Becton Dickinson's 11-year CEO Edward Ludwig plans to step down to make way for company veteran Vincent Florenza.

BDX

Becton, Dickinson & Co. (NYSE:BDX) picked a new man for the corner office this week with the announcement that Vincent Florenza will join the board of directors and take the reins from current board chairman and CEO Edward Ludwig on October 1, 2011.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Accuray announces $75 million offering | Funding Roundup

July 26, 2011 by MassDevice staff

Accuray Inc. announces plans to offer $75 million in convertible senior notes to institutional investors.

Accuray

Accuray Inc. (NSDQ:ARAY) announced plans to launch a $75 million offering of senior convertible notes today.

The notes, due Aug. 1, 2016, will be open to institutional investors and the Sunnyvale, Calif.-based company plans to offer the first investor an option to pick up an additional $11.25 million aggregate in principal notes.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Accuray closes $277 million TomoTherapy merger

June 13, 2011 by MassDevice staff

Accuray closes its $277 million buyout of TomoTherapy, doubling the radiosurgery device maker's footprint in the radiation oncology space.

Accuray_100_0.jpg

Accuray Inc. (NSDQ:ARAY) completed its $277 million acquisition of TomoTherapy Inc. (NSDQ:TOMO), tying the bow on a deal first announced in March 2010.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp